iSERA Lifesciences Limited

BSE:534920 Stock Report

Market Cap: ₹1.2b

iSERA Lifesciences Past Earnings Performance

Past criteria checks 3/6

iSERA Lifesciences has been growing earnings at an average annual rate of 48.8%, while the Software industry saw earnings growing at 19.6% annually. Revenues have been growing at an average rate of 5.1% per year. iSERA Lifesciences's return on equity is 3.1%, and it has net margins of 19%.

Key information

48.76%

Earnings growth rate

81.89%

EPS growth rate

Software Industry Growth22.64%
Revenue growth rate5.10%
Return on equity3.15%
Net Margin18.96%
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How iSERA Lifesciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BSE:534920 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2614310
31 Dec 255-110
30 Sep 253210
30 Jun 253110
31 Mar 253110
31 Dec 240-110
30 Sep 240-110
30 Jun 240-100
31 Mar 240-110
31 Dec 230-110
30 Sep 230-110
30 Jun 230-110
31 Mar 230-110
31 Dec 220-110
30 Sep 220-110
30 Jun 220-110
31 Mar 220-110
31 Dec 210-210
30 Sep 210-110
30 Jun 210-200
31 Mar 2121-220
31 Dec 200-310
30 Sep 200-410
30 Jun 2010-410
31 Mar 2021-410
30 Jun 19164-100
31 Mar 19257010
31 Mar 18336010
31 Mar 17241060
31 Mar 16255-13460
31 Dec 15203-6660
30 Sep 15167380

Quality Earnings: 534920 has a high level of non-cash earnings.

Growing Profit Margin: 534920's current net profit margins (19%) are lower than last year (52.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 534920 has become profitable over the past 5 years, growing earnings by 48.8% per year.

Accelerating Growth: 534920's earnings growth over the past year (86.6%) exceeds its 5-year average (48.8% per year).

Earnings vs Industry: 534920 earnings growth over the past year (86.6%) exceeded the Software industry 4.1%.


Return on Equity

High ROE: 534920's Return on Equity (3.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/10 15:12
End of Day Share Price 2026/07/09 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

iSERA Lifesciences Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.